0001179110-17-012517.txt : 20170920
0001179110-17-012517.hdr.sgml : 20170920
20170920173733
ACCESSION NUMBER: 0001179110-17-012517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170918
FILED AS OF DATE: 20170920
DATE AS OF CHANGE: 20170920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LYNCH DANIEL
CENTRAL INDEX KEY: 0001177082
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 171094693
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2017-09-18
0
0001597264
Blueprint Medicines Corp
BPMC
0001177082
LYNCH DANIEL
C/O BLUEPRINT MEDICINES CORPORATION
38 SIDNEY STREET, SUITE 200
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2017-09-18
4
S
0
2500
60.00
D
209342
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
/s/ Christopher Frankenfield, Attorney-in-Fact
2017-09-18